Personalized Medicine Forecast 2016 | Diaceutics

Personalized Medicine Forecast 2016

January 28th, 2016

Steve Vitale
Peter Keeling
Mark Reis

A forecast for the industry raises some interesting points. Will there be 50 per cent more targeted therapy launches in 2016? Are labs becoming the key pharma launch partners? Are payer value models finally get some traction? And how will companion and complementary diagnostics be defined?

Listen to this webinar to learn:

  • Insights on the latest trends in targeted therapies
  • Best practices for your companion and complementary diagnostics launch
  • What you should be thinking about for your successful launch

Expert Insights

April 19th, 2018
The CMS National Coverage Decision on NGS
I. Introduction On March 16, 2018, the Centers for Medicare and Medicaid Services (CMS) finalized a National Coverage Determination (NCD) that cove...
January 19th, 2018
What does the EU IVD Regulation mean for companion diagnostics and LDTs?
Dave Smart, PhD, Director at Diaceutics, discusses the introduction of the EU IVD Regulation. While it is considered a necessary step, the Regulati...
View all expert insights

Competitive Benchmarking Reports

March 16th, 2018
PM Readiness Report 2018 Summary
March 14th, 2017
Pharma Readiness for Diagnostic Integration 2017
View all reports


September 11th, 2018
BRAF mutation testing in melanoma – Poster presented at European Congress of Pathology 2018
BRAF mutation testing in melanoma: a study including Austria, Germany and UK, highlighting concordance for current technologies, and potential requirement of more sensitive technologies in future applications.
August 3rd, 2018
A Way Forward: Leveraging Advanced Diagnostic Testing to Unlock the Value of Precision Medicine
Read about how advanced diagnostic testing, ensuring that right patient gets the right therapy, at the right time, particularly with respect to therapies where the test result determines whether or not the therapy should be used (precision medicin...
View all publications